Vascular-targeting agent
Jump to navigation
Jump to search
A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.[1]
VTAs can be small-molecule or ligand-based.
Small-molecule VTAs include:
- microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
- vadimezan (ASA404)
Clinical trials
Phase II : ZD6126, CA4P, plinabulin (NPI-2358)[2][3][4]
Phase III : DMXAA (ASA404).
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".